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A B S T R A C T
Fibulin-4 is an extracellular matrix (ECM) protein essential for elastogenesis and mutations in this protein lead to
aneurysm formation. In this study, we isolated vascular smooth muscle cells (VSMCs) from mice with reduced
fibulin-4 protein expression (Fibulin-4R/R) and from mice with a smooth muscle cell specific deletion of the
Fibulin-4 gene (Fibulin-4f/−/SM22Cre+). We subsequently analyzed and compared the molecular consequences
of reduced Fibulin-4 expression versus total ablation of Fibulin-4 expression with regard to effects on the SMC
specific contractile machinery, cellular migration and TGFβ signaling.
Analysis of the cytoskeleton showed that while Fibulin-4f/−/SM22Cre+ VSMCs lack smooth muscle actin
(SMA) fibers, Fibulin-4R/R VSMCs were able to form SMA fibers. Furthermore, Fibulin-4f/−/SM22Cre+ VSMCs
showed a decreased pCofilin to Cofilin ratio, suggesting increased actin depolymerization, while Fibulin-4R/R
VSMCs did not display this decrease. Yet, both Fibulin-4 mutant VSMCs showed decreased migration. We found
increased activation of TGFβ signaling in Fibulin-4R/R VSMCs. However, TGFβ signaling was not increased in
Fibulin-4f/−/SM22Cre+ VSMCs.
From these results we conclude that both reduction and absence of Fibulin-4 leads to structural and functional
impairment of the SMA cytoskeleton. However, while reduced levels of Fibulin-4 result in increased TGFβ ac-
tivation, complete absence of Fibulin-4 does not result in increased TGFβ activation. Since both mouse models
show thoracic aortic aneurysm formation, we conclude that not only hampered TGFβ signaling, but also SMA
cytoskeleton dynamics play an important role in aortic aneurysmal disease.
1. Introduction
Aortic aneurysms are dilations of the aorta caused by a general
weakening of the aortic wall. Patients affected by such dilations have a
high risk of mortality upon rupture. Approximately 1–2% of all deaths
in the western world are caused by aortic aneurysms and dissections
[1]. The aortic wall consists of three layers, the intima, the media and
the adventitia. The medial layer of the aortic wall contains the elastic
laminae interspaced by vascular smooth muscle cells (VSMCs) and is
important for the elasticity and contractility of the ascending aorta.
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During aneurysm formation the medial layer of the aorta is character-
ized by elastin layer fragmentation, loss of VSMCs and deposition of
excess of extracellular matrix (ECM) material. These processes weaken
the aortic wall and increase the risk of rupture [1,2].
Multiple genes have been identified to cause aneurysm formation
when mutated. Mutations in the extracellular matrix protein fibrillin-1
(FBN1) lead to Marfan syndrome [3]. Mutations in proteins implicated
in TGFβ signaling, such as TGFβ receptor 1 and 2 (TGFβR1 and
TGFβR2) as well as SMAD3, lead to Loeys-Dietz syndrome character-
ized by aneurysm formation [4–8]. In addition, contractile or cytoske-
letal protein mutations, such as α-smooth muscle actin (ACTA2) and
myosin heavy chain 11 (MYH11) have been identified as causal genes
for aneurysm formation [9–12]. Although these proteins are localized
in different topological compartments, they most likely cooperate at a
mechanistic molecular level and collectively play a role in aneurysm
formation. We hypothesize that reduced presence or complete absence
of the extracellular matrix protein fibulin-4 could influence cytoske-
leton structure and dynamics since cell-ECM contact is mediated by
transmembrane cell adhesion receptors, such as integrins, that interact
with extracellular matrix proteins as well as a number of cytoplasmic
adaptor proteins that interact with the actin cytoskeleton or function in
signal transduction.
Fibulin-4 is an ECM protein that is essential for elastogenesis and is
responsible for the recruitment of lysyl oxidase [13]. Lysyl oxidase is
required for proper crosslinking of the elastin precursor tropoelastin to
form mature elastic laminae [14]. These elastic laminae are of im-
portance for the elasticity of the aorta and for deposition of latent TGFβ
complexes [15]. When fibulin-4 is absent or unable to recruit lysyl
oxidase, tropoelastin is not properly crosslinked. This leads to irregular
elastic laminae that have a fragmented appearance [16]. EFEMP2 (Fi-
bulin-4) mutations in patients lead to cutis laxa, an autosomal recessive
disease that is characterized by non-elastic and loose skin, aneurysms
and tortuosity of the large arteries [17–19]. Cutis laxa patients have
either reduced fibulin-4 protein levels in tissues, or reduced binding of
fibulin-4 to its targets. Furthermore, increased TGFβ signaling is de-
tected in these patients [17,20].
Different mouse models have been generated to investigate the role
of Fibulin-4 in aneurysm formation. While complete absence of Fibulin-
4 is perinatal lethal, hypomorphic mice with 4-fold reduced expression
levels (Fibulin-4R/R, in which ‘R’ indicates the reduced expression al-
lele) are viable [21,22]. Like cutis laxa patients, Fibulin-4R/R mice show
aortic aneurysm formation, elastic laminae fragmentation and in-
creased TGFβ signaling [22,23]. In addition, VSMC-specific knock-out
mice for Fibulin-4 (Fibulin-4f/−/SM22Cre+) also develop aneurysms
exclusively in the ascending aorta [24]. This mouse model has pre-
viously been used to determine the role of fibulin-4 in aortic develop-
ment, and is instrumental to determine the role of fibulin-4 in aneurysm
formation and VSMC function.
In this study we compared VSMCs isolated from aortas of Fibulin-
4R/R and Fibulin-4f/−/SM22Cre+ mice to analyze the consequences of
diminished and completely ablated Fibulin-4 expression on cytoske-
leton dynamics, cell movement and TGFβ signaling.
2. Materials and methods
2.1. Mice
Fibulin-4R/R and Fibulin-4f/−/SM22Cre+ were generated and de-
scribed previously [22,24]. Animals were housed at the Animal Re-
source Centre (Erasmus University Medical Centre), which operates in
compliance with the “Animal Welfare Act” of the Dutch government,
using the “Guide for the Care and Use of Laboratory Animals” as its
standard. As required by Dutch law, formal permission to generate and
use genetically modified animals was obtained from the responsible
local and national authorities. An independent Animal Ethics Com-
mittee consulted by Erasmus Medical Center (Stichting DEC Consult)
approved these studies (permit number 140-12-05), in accordance with
national and international guidelines. Animals were sacrificed by CO2
inhalation, unless stated otherwise. This study conforms to the guide-
lines from Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientific purposes or the NIH guidelines.
2.2. VSMC isolation and cell culture
Mice (at an age of 100 days) were euthanized and autopsied ac-
cording to standard protocols. Primary VSMCs from the thoracic aorta
were isolated according to the collagenase digestion method of
Proudfoot and Shanahan [25]. Each cell line was derived from a single
aorta. Fibulin-4+/+ and Fibulin-4f/+/SM22Cre+ VSMCs were used as
controls, in which Fibulin-4f/+/SM22Cre+ VSMCs also served as con-
trols for the potential toxic effects of Cre recombinase. Due to differ-
ences in the genetic background of the mice (Fibulin-4+/+ and Fibulin-
4R/R: C57Bl/6, Fibulin-4f/+/SM22Cre+ and Fibulin-4f/−/SM22Cre+:
C57Bl/6 and SJL), Fibulin-4f/+/SM22Cre+ VSMCs will be used as a
primary control for Fibulin-4f/−/SM22Cre+ VSMCs. Fibulin-4f/
+/SM22Cre+ VSMCs show a decrease in Fibulin-4 expression compared
to Fibulin-4+/+ VSMCs (Fig. 1A), due to the deletion of one floxed
allele by Cre recombinase. When experiments were performed si-
multaneously, we depicted all four genotypes (Fibulin-4+/+, Fibulin-
4R/R, Fibulin-4f/+/SM22Cre+ and Fibulin-4f/−/SM22Cre+) together.
In the figures, Fibulin-4f/+/SM22Cre+ and Fibulin-4f/−/SM22Cre+
VSMCs are referred to as Fibulin-4f/+ and Fibulin-4f/−, respectively.
Unless otherwise specified two cell lines were used per genotype. Pri-
mary VSMCs were cultured on gelatinized dishes in Dulbecco's Modified
Eagle's Medium (DMEM) (Lonza BioWhittaker) supplemented with 1%
penicillin-streptomycin (PS) and 10% fetal calf serum (FCS).
2.3. RNA isolation and real-time PCR
RNA from VSMCs was isolated with the RNeasy mini kit (Qiagen).
cDNA was made with iScript cDNA synthesis kit (Biorad) according to
manufacturing protocol. Q-PCR was performed with 200 nM forward
and reverse primers and iQ™ SYBR® Green Supermix (Biorad) on the
CFX96 system (Biorad); denaturation at 95 °C for 3min, 40 cycles de-
naturation at 95 °C for 15 s, annealing/extension at 55 °C for 30 s. B2M
and β-actin were used as reference genes and gave similar expression.
Data is shown with B2M as a reference gene. Relative gene expression
levels were determined with the comparative Ct (also referred to as
ΔΔCt) method according to the MIQE guidelines. See Table 1 for pri-
mers used. Number of replicates is specified in the figure legends.
2.4. Western blotting
Western blot analysis was performed to determine protein amounts
in extracts of Fibulin-4f/−/SM22Cre+ and Fibulin-4R/R VSMCs com-
pared to their controls. Cultured VSMCs were scraped in PBS supple-
mented with protease inhibitor cocktail (1:100, 11,836,145,001, Roche
applied science) and phosphatase inhibitor cocktail (1:100, P0044,
Sigma) and lysed in an equal volume of 2× Laemmli buffer (4% SDS,
20% glycerol, 120mM Tris pH 6,8) supplemented with protease in-
hibitor cocktail and phosphatase inhibitor. Lysates first cleared from
large DNA by passing through a 25G needle and then heated to 65 °C for
10min. Protein concentrations were measured with the Lowry protein
Table 1
Primer sequences used for real-time PCR.
Gene Fw sequence Rev sequence
Fibulin-4 GGGTTATTTGTGTCTGCCTCG TGGTAGGAGCCAGGAAGGTT
B2M CTCACACTGAATTCACCCCCA GTCTCGATCCCAGTAGACGGT
β-actin AGATCAAGATCATTGCTCCTCCTG GGGTGTAAAACGCAGCTCAG
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assay as described [26]. Equal amounts of protein (10 μg per sample)
were separated for size by SDS-PAGE and then transferred to a PVDF
membrane (1 h, 100 V, Immobilon) and blocked with either 3% milk or
5% BSA in PBS supplemented with 0.1% Tween-20 (1 h, room tem-
perature). The primary antibody was incubated overnight at 4 °C (see
Table 2 for primary antibodies). The membranes were washed 5 times
with 0.1% Tween-20 in PBS and then incubated with horseradish per-
oxidase-conjugated secondary antibodies (1:2000, Jackson Im-
munoResearch) for 1 h at room temperature. Bound secondary anti-
bodies were detected with an Amersham Imager 600 (GE Healthcare
Life Sciences) using chemiluminescence. Band intensity was quantified
using Fiji image analyzing software [27]. Number of replicates is spe-
cified in the figure legends.
2.5. Immunofluorescence
For in situ visualization of actin fibers, α-SMA and paxillin, VSMCs
were seeded on 0.01% collagen coated coverslips and allowed to attach
for 48 h. VSMCs were fixed with 2% paraformaldehyde in PBS for
15min. After fixation coverslips were washed with PBS with 0.1%
Trition-X100 and blocked with PBS+ (PBS supplemented with 0.15%
glycine and 0.5% bovine serum albumin) for 30min. Primary anti-
bodies were incubated overnight at 4 °C in PBS+, α-SMA (1:750,
ab7871, Abcam) and Paxillin (1:400, ab32115, Abcam). Coverslips
were washed with PBS with 0.1% trition-X100 and incubated shortly
with PBS+ prior to incubation with the secondary antibody in PBS+
(1:1000, anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594,
Molecular Probes) at RT for 1 h. After incubation the coverslips were
mounted on glass slides with Vectashield supplemented with DAPI (H-
1200, Vector laboratories) and sealed with nail polish. Images were
recorded on a wide field epifluorescent microscope (Axio Imager D2,
Zeiss).
2.6. Live cell imaging
VSMCs were seeded at a density of 10,000 cells/cm2 on a 0.01%
collagen coated coverslip. VSMCs were allowed to attach for 48 h prior
to transfection with a Paxillin-EGFP construct (2 μg/6-well) using
Lipofectamin 3000 (L3000-015, Thermo Fisher). Plasmid pPaxillin-
EGFP encodes an Paxillin-EGFP fusion protein, consisting of the chicken
(Gallus gallus) paxillin protein fused to EGFP through a 22 amino acid
linker. Plasmid pPaxillin-EGFP was made by substituting the
mTurquoise cDNA in plasmid pmTurquoise-Paxillin-22 (Addgene
plasmid # 55573) for the EGFP cDNA from plasmid pEGFP-N1
(Clontech) as a BamH1/NotI DNA fragment. After 6 h, the transfection
medium was replaced with regular medium and VSMCs were allowed to
recover overnight. The medium was replaced with medium supple-
mented with 150 nM SiR-Actin (SC001, Cytoskeleton, Inc.) to label
actin filaments. After 6 h the VSMCs were imaged overnight with a
confocal laser scanning microscope, Leica SP5 microscope (Leica,
Mannheim). Images were recorded every 10min at three levels of the
cell (base, middle and top, 1 μm separated from each other). Movement
of the VSMCs was quantified by Fiji image analysis software. After
delineating the maximum projection, VSMCs were manually tracked
with MTrackJ [28]. Total length of the path was used for comparing the
mean migration velocity of Fibulin-4f/+, Fibulin-4f/−, Fibulin-4+/+
and Fibulin-4R/R VSMCs.
2.7. G-actin/F-actin in vivo assay
The ratio between filamentous actin and monomeric actin was de-
termined with a G-actin/F-actin in vivo assay kit (BK037, Cytoskeleton,
Inc.). Two days prior to the experiment, VSMCs were seeded on 0.01%
collagen coated wells to reach an almost confluent density at the time of
lysis. Manufacturer protocol was followed for the lysis and fractionation
of the F- and G-actin, ultracentrifugation of the samples was performed
at room temperature. Equal volumes of supernatant (G-actin) and pellet
(F-actin) lysates (10 μl per sample) were run on 12% gels according to
the above described Western blotting protocol. Analysis of the fractions
was performed with Fiji image analysis software. Number of replicates
is specified in the figure legends.
2.8. Immunofluorescence of extracellular matrix
ECM protein production by VSMCs was determined by immuno-
fluorescence. VSMCs were seeded at 25,000 cells/well, except for
Fibulin-4 staining that required a higher seeding density of 75,000
cells/well, in 8-well removable chamber slides and grown in DMEM
supplemented with 10% heat-inactivated FCS and 1% PS for 7 days to
allow ECM deposition. VSMCs were fixed with an ice-cold 70:30 me-
thanol:acetone mixture for 5min and washed with PBS. Coverslips were
blocked for 1 h with PBS supplemented with 10% normal goat serum
(X0907, Agilent). Primary antibodies (Table 3) were incubated over-
night at 4 °C in PBS. Coverslips were washed three times with PBS for
5min each prior to incubation with the secondary antibody for 1.5 h at
room temperature (1:1000, anti-rabbit Alexa Fluor 594, Molecular
Probes). Coverslips were washed and mounted to glass slides with
Vectashield supplemented with DAPI (H-1200, Vector laboratories) and
Table 2
Antibodies used for Western blot analysis.
Primary antibody Predicted kDa Dilution Manufacturer Catalog number
Mouse α-β actin IgG2b 43 1:500.000 Merck Millipore MAB1501
Mouse α-SMA IgG2a 40 1:10.000 Abcam Ab7817
Rabbit α-SM22 IgG 23 1:2000 Abcam Ab14106
Rabbit α-Cofilin IgG 19 1:2000 Abcam Ab11062-50
Rabbit α-pCofilin (Ser3) IgG 19 1:1000 Cell signaling 3313S
Rabbit α-SMAD2 IgG 60 1:1000 Cell signaling 5339S
Rabbit α-pSMAD2 IgG 55–60 1:400 Merck Millipore 04-953
Mouse α-β catenin IgG1 92 1:2000 BD Bioscience 610153
Table 3
Antibodies used for immunofluorescent staining of the ECM.
Primary antibody Dilution Manufacturer Catalog number
Rabbit α-fibronectin IgG 1:80 Millipore AB2033
Rabbit α-mouse fibrillin-1 1:1000 Generated in Reinhardt Lab –
Rabbit α-mouse LTBP4 1:1000 Generated in Reinhardt Lab –
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sealed with nail polish. Images were recorded on a wide field epi-
fluorescent microscope (Axio Imager D2, Zeiss). Fibulin-4 images were
recorded on a Axio Imager M2 epifluorescent microscope, Zeiss.
2.9. TGFβ reporter assay
Downstream activation of the TGFβ pathway was determined via a
CAGA-MLP-luciferase promoter reporter construct [29]. This construct
contains palindromic repeats of the SMAD3/SMAD4 binding site of the
PAI-1 promoter and was shown to be sensitive to TGFβ [29]. VSMCs
were seeded the day prior to transfection in gelatinized 24 well plates.
Subconfluent cells were transfected with Lipofectamin 3000 according
to the manufacturer protocol. A SV40-renilla construct (Addgene
plasmid # 27163, [30]) was co-transfected to correct for transfection
efficiency. After 6 h, the transfection medium was replaced with DMEM
supplemented with 10% FCS and 1% PS. On the following day the
VSMCs were serum starved for 2 h by DMEM supplemented with 0.2%
FCS and 1% PS. The VSMCs were then treated overnight with serum
starvation medium supplemented with 5 ng/ml TGFβ1 (4342-5, Biovi-
sion) or 10 μM SB43542 hydrate (S4317-5mg, Sigma) or without sti-
mulation. VSMCs were washed with PBS, lysed and luciferase activity
was measured with the dual-luciferase kit (E1910, Promega) with the
GloMax-multi detection system (Promega). Number of replicates is
specified in the figure legends.
2.10. Statistical analysis
All experiments were performed in triplicate using three in-
dependent samples. Data were corrected for outliers with the Grubbs'
test for outliers. Statistical analysis was performed with a non-para-
metric Mann-Whitney test. Significance was tested 2-tailed. A p-
value< .05 was considered to indicate a significant difference between
groups. In the figures p < .05 is show with *, p < .01 with $,
p < .001 with ‡, and p < .0001 with #. Results are expressed as
mean ± SD, real-time PCR results are expressed as geometric
mean ± geometric SD. All analyses were performed using Graphpad,
version 7.03.
3. Results
3.1. Fibulin-4 mutations affect the SMA cytoskeleton
To compare the consequences of complete Fibulin-4 deletion versus
decreased expression of Fibulin-4, we isolated VSMCs from aortas of
Fibulin-4f/−/SM22Cre+ (VSMC-specific deletion of the Fibulin-4 gene)
and Fibulin-4R/R (reduced expression of the Fibulin-4 gene) animals and
their respective control littermates. First, Fibulin-4 gene expression was
determined in Fibulin-4R/R, Fibulin-4f/−/SM22Cre+, Fibulin-4+/+ and
Fibulin-4f/+/SM22Cre+ VSMCs. Fibulin-4 expression in Fibulin-4R/R
VSMCs is approximately 20% of the Fibulin-4+/+ VSMCs (Fig. 1A). No
Fibulin-4 expression was detected in Fibulin-4f/−/SM22Cre+ VSMCs
while Fibulin-4 gene expression was present in the control Fibulin-4f/
+/SM22Cre+ VSMCs, but significantly reduced to about 50% compared
to Fibulin-4+/+ (Fig. 1A).
Previously Huang et al. have shown that VSMC-specific deletion of
Fibulin-4 leads to decreased expression of ACTA2 in Fibulin-4f/
−/SM22Cre+ aortas, indicating that absence of Fibulin-4 impairs dif-
ferentiation and proper SMA cytoskeleton formation [24]. To further
analyze these isolated VSMCs, cells were stained for SMA and paxillin.
SMA is a marker for the contractile, non-proliferative phenotype of
adult VSMCs and paxillin is a multidomain adaptor localized at the
interface between the plasma membrane and the actin cytoskeleton.
The control VSMCs, Fibulin-4f/+/SM22Cre+ and Fibulin-4+/+ showed
numerous SMA stress fibers spanning their cytoplasm (Fig. 1B). The
well spread controls adhered to the surface with elongated focal con-
tacts positive for paxillin, positioned at the end of the individual SMA
fibers (Fig. 1C, top and bottom image). The arrows indicate the overlay
between SMA fibers and the focal adhesions in yellow. In Fibulin-4f/
−/SM22Cre+ VSMCs SMA stress fibers were not present and paxillin
staining identified small rounded podosome-like structures instead of
the elongated structures observed in control VSMCs. This was further
confirmed in higher magnification images (Fig. 1C and D). The Fibulin-
4R/R VSMC did show SMA stress fibers, however, these fibers were not
as distinct as in control VSMCs. Yet, paxillin did localize to the ends of
SMA fibers and also formed elongated structures as was seen in the
control VSMCs. Western blotting on whole cell lysates showed presence
of SMA in both the Fibulin-4f/+/SM22Cre+ and the Fibulin-4+/+
control VSMCs. Compared to the Fibulin-4f/+/SM22Cre+ and Fibulin-
4+/+ VSMCs SMA expression was significantly decreased in Fibulin-4f/
−/SM22Cre+ (Fig. 1E and F, p < .0001). In contrast, Fibulin-4R/R
VSMCs whole cell lysates showed an increase in SMA protein levels
compared to Fibulin-4+/+ whole cell lysates (Fig. 1E and F,
p < .0001). Similarly, Fibulin-4f/+/SM22Cre+ VSMCs with 50% Fi-
bulin-4 gene expression showed a significant increase in SMA protein
compared to Fibulin-4+/+ VSMCs (Fig. 1E and F, p < .0001).
These results show that complete absence of Fibulin-4 leads to loss
of SMA stress fibers, while reduced levels of Fibulin-4 can support SMA
fiber formation. However, this fiber formation appears affected, even
though the total amount of SMA protein is increased in Fibulin-4R/R
VSMCs. Furthermore, absence of Fibulin-4 in the Fibulin-4f/
−/SM22Cre+ VSMCs also leads to an aberrant, podosome-like, ap-
pearance of the focal adhesion structures.
3.2. Actin dynamics are differentially affected by Fibulin-4 mutations
The actin cytoskeleton is a dynamic structure in which actin
monomers are continuously polymerized and depolymerized. The lack
of SMA fibers in Fibulin-4f/−/SM22Cre+ VSMCs suggests less poly-
merization of actin monomers into actin fibers or, alternatively, in-
creased depolymerization in Fibulin-4f/−/SM22Cre+ VSMCs.
Previously, alteration in actin depolymerization in Fibulin-4f/
−/SM22Cre+ aortic tissue lysates has been linked to decrease in
phosphorylated cofilin to total cofilin ratio and the restoration of cofilin
phosphorylation prevented aneurysm formation [31]. This shift in-
creases activity of cofilin leading to increased depolymerization of the
actin fibers. In addition, SM22, an actin crosslinking protein and VSMC
differentiation marker, is decreased in Fibulin-4f/−/SM22Cre+ aortic
tissue lysates, suggesting that the VSMCs are not fully differentiated
into mature VSMCs when Fibulin-4 is completely absent [31–33].
To determine if actin is still polymerized in mature actin filaments
in Fibulin-4f/−/SM22Cre+ VSMCs and Fibulin-4R/R VSMCs, we per-
formed an F-/G-actin fractionation by which the ratio of polymerized
versus free actin monomers can be determined (Fig. 2A and B). This
fractionation revealed a decrease in F-actin levels over G-actin levels in
Fibulin-4f/−/SM22Cre+ VSMCs compared to control Fibulin-4f/
+/SM22Cre+ VSMCs (Fig. 2B, p < .01). No significant difference in F-
actin/G-actin fraction was found in Fibulin-4R/R VSMCs compared to
Fibulin-4+/+ VSMCs (Fig. 2B). The F-actin/G-actin fraction of Fibulin-
4f/−/SM22Cre+ VSMCs was also significantly decreased compared to
both Fibulin-4+/+ and Fibulin-4R/R VSMCs (Fig. 2B, p < .05).
The ratio of phosphorylated cofilin to cofilin was determined by
western blot analysis to analyze the amount of inactive to active cofilin,
respectively. We observed a decrease in the phosphorylated cofilin to
cofilin ratio in Fibulin-4f/−/SM22Cre+ VSMCs compared to Fibulin-
4+/+ VSMCs (Fig. 2C and D, p < .01). This shift in ratio towards more
active cofilin leads to increased depolymerization of actin fibers in Fi-
bulin-4f/−/SM22Cre+ VSMCs. In Fibulin-4R/R VSMCs the ratio of
phosphorylated cofilin to cofilin was comparable to Fibulin-4+/+
VSMCs (Fig. 2C and D). When comparing the ratio of phosphorylated
cofilin to cofilin in Fibulin-4f/+/SM22Cre+ VSMCs no difference was
found compared to Fibulin-4+/+ VSMCs (Fig. 2C and D).
Western blot analysis for SM22 protein levels was performed to
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Fig. 1. Fibulin-4 is needed for SMA fiber formation. A) Relative gene expression of Fibulin-4 in Fibulin-4+/+, Fibulin-4R/R, Fibulin-4f/+ and Fibulin-4f/− VSMCs. Data
is shown for n=3–7 lysates in 2 independent experiments. B) Immunofluorescent staining of SMA in green and paxillin in red. Scale bar represents 50 μm. C) Close
up of paxillin and SMA staining. Paxillin forms elongated structures that localize to the tips of SMA fibers in Fibulin-4+/+ and Fibulin-4f/+ VSMCs (arrow indicates
an example of overlap between SMA and paxillin). In Fibulin-4f/− VSMCs paxillin did not localize to SMA fibers and formed small rounded podosome-like structures
(one example shown in circle). Scale bar represents 10 μm. D) Further close-up of actin fibers and paxillin overlay in Fibulin-4f/+ and podosome-like structures of
paxillin in Fibulin-4f/− VSMC. Scale bar represent 10 μm. E) Western blots detecting SMA in Fibulin-4+/+, Fibulin-4R/R, Fibulin-4f/+ and Fibulin-4f/− VSMC protein
extracts. β-catenin levels serve as a loading control. F) Quantification of SMA levels as shown in panel E, respectively. Data is shown for n=7–8 lysates in 3
independent experiments. Bars represent mean ± SD. Mann-Whitney test. $ p < .01, # p < .0001.
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assess the differentiation status of the VSMCs and the actin crosslinking
potential in Fibulin-4f/−/SM22Cre+ and Fibulin-4R/R VSMCs. SM22
protein levels were significantly lower in Fibulin-4f/−/SM22Cre+
VSMCs compared to Fibulin-4f/+/SM22Cre+ VSMCs (Fig. 2F and G,
p < .0001). In Fibulin-4R/R VSMCs, SM22 protein levels were in-
creased compared to Fibulin-4+/+ VSMCs (Fig. 2F and G, p < .05).
Similarly, when comparing Fibulin-4f/+/SM22Cre+ VSMCs to Fibulin-
4+/+, SM22 protein levels were increased in Fibulin-4f/+/SM22Cre+
VSMCs (Fig. 2F and G, p < .0001). Hence, reduction of Fibulin-4 leads
to increased SM22 levels, whereas complete absence of Fibulin-4 leads
to reduced SM22.
These results show that the actin dynamics are altered in both
Fibulin-4f/−/SM22Cre+ VSMCs as well as Fibulin-4R/R VSMCs. While
Fibulin-4f/−/SM22Cre+ VSMCs showed a decreased F-actin fraction,
increased depolymerization and decreased SM22 levels, Fibulin-4R/R
VSMCs showed no decrease in F-actin fraction and, opposite to Fibulin-
4f/−/SM22Cre+ VSMCs increased SM22 protein levels.
3.3. Migration is disturbed by Fibulin-4 mutations
We subsequently investigated whether the changes in cytoskeletal
composition and actin (de)polymerization have implications for spon-
taneous cellular migration. We stained the overall actin cytoskeleton
present in all cells (in contrast to the VSMC specific actin protein, SMA),
by addition of the SiR-Actin probe, which is incorporated into the actin
cytoskeleton and allows monitoring of cellular migration and mea-
suring migration velocity by live cell imaging.
During cellular migration, new actin fibers and focal adhesions are
formed in the direction of migration, while actin fibers are depoly-
merizing and focal adhesions are detaching at the back of the cell. Live
cell imaging of VSMCs labeled with SiR-Actin and overexpression of the
focal adhesion protein paxillin-eGFP displays this directional migration
(online, Movie_1). Fig. 3A displays a limited set of frames from these
live cell movies with the arrows indicating migration direction. A close
up of a Fibulin-4f/+/SM22Cre+ VSMC shows the formation of new
focal adhesions in the direction of movement and disappearance of
focal adhesions at the detaching side of the cells. Interestingly, Fibulin-
4f/−/SM22Cre+ VSMCs showed formation of new focal adhesions
evenly distributed around the entire cell membrane and migration of
individual cells occurs in all directions. Since this direction of migration
occurred simultaneously in opposite directions, this resulted in reduced
effective migrations and expansion of individual cells (Fig. 3A and
online, Movie_2).
To obtain an overview of migration and to quantify migration ve-
locity cells were imaged at lower magnification. Fibulin-4f/
−/SM22Cre+ VSMCs showed a shorter path length compared to
Fibulin-4f/+/SM22Cre+ VSMCs and thus less migration. When total
migration was corrected for time, migration velocity was obtained.
Fibulin-4f/−/SM22Cre+ VSMCs showed a decreased migration velocity
compared to control VSMCs (Fig. 3B, p < .001). Fibulin-4R/R VSMCs
Fig. 1. (continued)
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Fig. 2. Altered cytoskeleton dynamics in Fibulin-4R/R and Fibulin-4f/− VSMCs. A) Western blot of F−/G-actin containing fractions in Fibulin-4+/+, Fibulin-4f/+,
Fibulin-4R/R, and Fibulin-4f/− VSMC protein extracts. B) Quantification of F-actin to G-actin ratio. Data is shown for n=2 samples in 3 independent experiments. C)
Western blot detecting pCofilin, Cofilin and loading control β-catenin in Fibulin-4+/+, Fibulin-4R/R, Fibulin-4f/+ and Fibulin-4f/− VSMC protein extracts. D)
Quantification of pCofilin/Cofilin ratio. Data is shown for n=4–6 samples in 3 independent experiments. E) Western blot for SM22 and loading control β-catenin for
Fibulin-4+/+, Fibulin-4R/R, Fibulin-4f/+ and Fibulin-4f/− VSMC protein extracts. F) Quantification of SM22 shown in E). Data is shown for n=4 lysates in 3
independent experiments. Bars represent mean ± SD. Mann-Whitney test. * p < .05, $ p < .01, # p < .0001.
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also showed decreased migration velocity compared to Fibulin-4+/+
VSMCs (Fig. 3B, p < .0001). Unlike Fibulin-4f/−/SM22Cre+ VSMCs,
directionality of movement was seen in Fibulin-4R/R VSMCs. Migration
velocity did not differ between Fibulin-4f/+/SM22Cre+ and Fibulin-
4+/+ VSMCs. Example movies can be found online (Movie_3 to
Movie_6).
Taken together these data show that when Fibulin-4 is absent or
reduced, VSMCs exhibit decreased migration and have a lower migra-
tion velocity compared to control cells.
3.4. Analysis of ECM production and TGFβ signaling pathway in Fibulin-4f/
−/SM22Cre+ and Fibulin-4R/R VSMCs
Since fibulin-4 plays an important role in ECM integrity and both
Fibulin-4R/R and Fibulin-4f/−/SM22Cre+ mutant VSMCs show de-
creased migration, we investigated whether this similarity in aberrant
movement was caused by similar changes in ECM composition.
Immunofluorescent staining of the ECM components, fibulin-4, fi-
bronectin-1, fibrillin-1 and latent TGFβ binding protein 4 (LBTP4), was
performed after 7 days of culture to asses ECM production in both types
of Fibulin-4 mutant VSMCs.
Fibulin-4 is essential for elastogenesis and recruitment of lysyl
oxidase. Lysyl oxidase is needed for crosslinking of the elastin precursor
tropoelastin and the formation of mature elastic laminae. In contrast to
Fibulin-4+/+ VSMCs, Fibulin-4R/R VSMCs do not show a clear network
of fibulin-4 fibers (Fig. 4A). Fibulin-4f/+/SM22Cre+ VSMCs do show
fibulin-4 fibers, however, with less intensity than Fibulin-4+/+ VSMCs
(Fig. 4A). In Fibulin-4f/−/SM22Cre+ VSMCs fibulin-4 fibers and pro-
tein are not detectable (Fig. 4A). Fibronectin serves as a base network
on which other ECM proteins are deposited. Therefore, production of
fibronectin is essential for proper ECM formation. A more extensive
network of fibronectin fibers were apparent in Fibulin-4R/R VSMCs
compared to Fibulin-4+/+ VSMCs, (Fig. 4B). In contrast, Fibulin-4f/
−/SM22Cre+ VSMCs produced a minimal amount of fibronectin fibers
compared to Fibulin-4f/+/SM22Cre+ and Fibulin-4+/+ VSMCs. Fi-
bulin-4f/+/SM22Cre+ VSMCs show a slight increase in fibronectin fi-
bers compared to Fibulin-4+/+ VSMCs. Fibrillin-1 is the central com-
ponent of microfibrils and is important for structural support in tissues
and elastic fiber formation. Similarly to the fibronectin network, the
fibrillin-1 fiber network of Fibulin-4R/R VSMCs is more extensive than
of Fibulin-4+/+ VSMCs (Fig. 4C). However, Fibulin-4f/−/SM22Cre+
VSMCs show a less extensive fibrillin-1 fiber network compared to Fi-
bulin-4f/+/SM22Cre+ and Fibulin-4+/+ VSMCs. Like the fibronectin
fibers, Fibulin-4f/+/SM22Cre+ VSMCs show a slight increase in fi-
brillin-1 fibers compared to Fibulin-4+/+ VSMCs (Fig. 4C). LTBP4
binds inactive TGFβ to the ECM where it is stored until activation oc-
curs. LTBP4 is of importance for the bioavailability of TGFβ and,
therefore, activation of the TGFβ signaling pathway. While LTBP4 is
detected in Fibulin-4f/−/SM22Cre+ VSMCs and fibers are formed, the
number of LTBP4 fibers is far less compared to Fibulin-4f/+/SM22Cre+
VSMCs. Fibulin-4R/R VSMCs showed increased staining of LTBP4 pre-
sent in an extensive ECM network compared to Fibulin-4+/+ VSMCs.
Again, Fibulin-4f/+/SM22Cre+ VSMCs show a slight increase in LTBP4
compared to Fibulin-4+/+ VSMCs (Fig. 4D). The slight increase in ECM
production by Fibulin-4f/+/SM22Cre+ VSMCs could explained by the
reduced expression of fibulin-4. In conclusion, this suggests that a re-
duction in fibulin-4 results in upregulation of ECM deposition but a
complete absence of fibulin-4 abolishes the deposition/assembly of
various ECM proteins.
The difference in ECM deposition found between Fibulin-4R/R and
Fibulin-4f/−/SM22Cre+ VSMCs could indicate differential activities of
the TGFβ pathway signaling in both mutants. Hence, we next per-
formed analysis of TGFβ signaling components as well as TGFβ
pathway activation. To determine if Fibulin-4f/−/SM22Cre+ VSMCs
show increased TGFβ signaling, we performed western blotting to de-
termine the phosphorylation status of SMAD2 (pSMAD2) (Fig. 4E and
F). While SMAD2 protein levels were comparable, Fibulin-4f/
−/SM22Cre+ cell lysates showed lower pSMAD2 protein levels
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compared to Fibulin-4f/+/SM22Cre+ lysates. (Fig. 4E). Fibulin-4R/R
VSMC whole cell lysates showed higher pSMAD2 protein levels com-
pared to Fibulin-4+/+ lysates as also previously observed (Fig. 4E)
[23]. Quantification of the pSMAD2 and SMAD2 levels showed a sig-
nificant decrease in pSMAD2/SMAD2 ratio in Fibulin-4f/−/SM22Cre+
VSMCs compared to Fibulin-4f/+/SM22Cre+ lysates (Fig. 4F, p < .05),
while Fibulin-4R/R VSMCs showed an increased pSMAD2/SMAD2 ratio
compared to its control (Fig. 4F, p < .05).
To examine downstream activation of the TGFβ pathway, a TGFβ
reporter assay was performed. In this assay PAI-1 promoter activation,
represented by luciferase activity, is measured. PAI-1 can be activated
by binding of the phosphorylated SMAD2/SMAD3 complex. Fibulin-4R/
R VSMCs showed spontaneous increased TGFβ signaling pathway acti-
vation compared to Fibulin-4+/+ VSMCs (Fig. 4G, p < .001). Our
previous research on Fibulin-4R/R VSMCs showed that increased TGFβ
signaling could be reduced by treatment of the cells with SB431542
hydrate, a TGFβ receptor blocker [23]. As visualized in Fig. 4H, the
intrinsic, cell autonomous TGFβ signaling pathway activation in Fi-
bulin-4f/−/SM22Cre+ VSMCs was decreased compared to Fibulin-4f/
+/SM22Cre+ VSMCs (p < .05). When TGFβ signaling was inhibited by
SB431542 hydrate in Fibulin-4f/−/SM22Cre+ VSMCs there was no
significant decrease in PAI-1 promoter, while Fibulin-4R/R VSMCs did
show such a decrease in PAI-1 promoter activation after treatment with
SB431542 hydrate (Fig. 4 I and J).
When stimulated with TGFβ, the TGFβ pathway can be activated in
Fibulin-4f/−/SM22Cre+ VSMCs as well as in Fibulin-4R/R VSMCs
(Fig. 4K and L, p < .0001). Western blot analysis of protein lysates of
VSMCs stimulated with and without TGFβ further showed increased
pSMAD2 levels after TGFβ stimulation. Interestingly, stimulation with
TGFβ increased SMA protein levels in Fibulin-4f/−/SM22Cre+ VSMCs
compared to non-stimulated Fibulin-4f/−/SM22Cre+ VSMCs. However,
it did not increase SM22 protein levels. Fibulin-4R/R VSMCs also
showed increased pSMAD2 protein levels upon TGFβ stimulation. A
further increase of TGFβ signaling in Fibulin-4R/R VSMCs did not result
in a large increase in SMA and SM22 protein levels.
4. Discussion
Our current data reveal that actin cytoskeleton structure and dy-
namics are affected in both Fibulin-4f/−/SM22Cre+ as well as Fibulin-
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Fig. 3. Fibulin-4f/− and Fibulin-4R/R VSMCs show less migration. A) Selected frames of live cell imaging (online movie_1 and movie_2) showing the migration of
Fibulin-4f/+ and Fibulin-4f/− VSMCs. Paxillin overexpression is depicted in green and actin (SiR-Actin) is depicted in red. Direction of movement is indicated by the
arrows. Scale bars equals 50 μm. B) Quantification of migration velocity of Fibulin-4+/+, Fibulin-4R/R, Fibulin-4f/+ and Fibulin-4f/− VSMCs (online movie_3,
movie_4, movie_5 and movie_6). Bars represent mean ± SD. Mann-Whitney test, ‡ p < .01 # p < .0001.
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4R/R VSMCs. Strikingly, we show that while TGFβ activation is in-
creased in VSMCs when Fibulin-4 levels are reduced (Fibulin-4R/R), no
changes in the activation of TGFβ signaling are observed in the absence
of Fibulin-4 (Fibulin-4f/−/SM22Cre+). Thus, a complete absence versus
reduced levels of Fibulin-4 differentially affects TGFβ signaling, in-
tracellular cytoskeleton structures and consequently cell movement.
Both the Fibulin-4R/R and Fibulin-4f/−/SM22Cre+ mouse model
show aortic aneurysm formation. Histological analysis of the aortas
shows fragmentation of the elastic laminae and thickening of the aortic
wall in both models. However, there are striking differences between
these models. The fragmentation of the elastic laminae differs between
the two models. Although Fibulin-4f/−/SM22Cre+ aortas show severe
fragmentation, it appears that the first elastic laminae adjacent to the
endothelial layer remain intact [22,24]. In Fibulin-4R/R aortas elastic
laminae throughout the entire media are fragmented. In this respect,
the affected cell populations in each model might explain this differ-
ence; in Fibulin-4R/R mice all cells have reduced Fibulin-4 expression,
while in Fibulin-4f/−/SM22Cre+ mice Fibulin-4 is specifically deleted
in VSMCs, surrounded by wild-type endothelial cells and fibroblasts.
Which is the reason why in this study we compared VSMCs from both
models.
Our data showed that both Fibulin-4 models display changes in their
cytoskeleton composition. Previous research by Huang et al. has shown
that aortas of Fibulin-4 germline knock-out embryos (Fibulin-4GKO)
contain less SMA [24]. Fibulin-4GKO VSMCs also displayed less distinct
actin fibers upon detection with phalloidin. Gene expression of ACTA2
and SM22 is decreased in Fibulin-4f/−/SM22Cre+ aortas [24,31],
which is in accordance with our results of decreased SMA and SM22
protein levels in Fibulin-4f/−/SM22Cre+ VSMCs. Although we find
decreased SM22 protein levels in Fibulin-4f/−/SM22Cre+ VSMCs, the
SM22 promoter must have been active during development, as the Cre
expression in the VSMC specific Fibulin-4 knock out is regulated by the
SM22 promotor. Decreased presence of SMA has previously also been
found by Arnold et al. in a neural crest cell specific knock-out of in-
tegrin linked kinase (ILK) [34]. Wnt1cre; Ilkflox/flox embryos present
with a severe aneurysmal arterial trunk, which leads to embryonic
lethality during late gestation. Decreased differentiation of smooth
muscle tissue has been observed as well as disorganization of F-actin
stress fibers. In addition, these embryos have decreased pSmad3
staining. The similarities in the Fibulin-4f/−/SM22Cre+ model and the
Wnt1cre; Ilkflox/flox model highlights a fundamental basis for the me-
chanistic link between the TGFβ signaling and proper cytoskeleton
Fig. 4. Analysis of ECM production and TGFβ signaling in Fibulin-4R/R and Fibulin-4f/− VSMCs. Immunofluorescent staining of production of ECM proteins by
VSMCs after 7 days in culture. Representative images are shown, scale bar is 100 μm. A) Immunofluorescent staining of fibulin-4. B) Immunofluorescent staining of
fibronectin. C) Immunofluorescent staining of fibrillin-1. D) Immunofluorescent staining of latent TGFβ binding protein (LTBP4). E) Western blots for pSMAD2,
SMAD2 and loading control β-catenin for Fibulin-4+/+, Fibulin-4f/+, Fibulin-4R/R and Fibulin-4f/− VSMC protein extracts. F) Quantification of pSMAD2/SMAD2
ratio. Data is shown for n=2–3 lysates in 3 independent experiments. G) Luciferase TGFβ transcriptional based assay showing increased activation of the PAI-1
promoter in Fibulin-4R/R VSMCs compared to Fibulin-4+/+ VSMCs. n=3 independent experiments in triplicate. H) Luciferase TGFβ transcriptional based assay
showing a decrease in pathway activation in Fibulin-4f/− VSMCs compared to Fibulin-4f/+ VSMCs. n=3 independent experiments in triplicate. I) and J) Luciferase
TGFβ transcriptional based assay showing no decrease in pathway activation after TGFβ inhibition in Fibulin-4f/−, while Fibulin-4R/R VSMCs do show decreased
TGFβ pathway after inhibition. Data is shown for 3 independent experiments with n=3–4 samples. K) Luciferase TGFβ transcriptional based assay showing
increased pathway activation after TGFβ stimulation in Fibulin-4R/R VSMCs. Data is shown for 3 independent experiments with n=4 samples. Western blots for
pSMAD2, SMAD2, SMA, SM22 and loading control β-catenin for Fibulin-4R/R VSMC protein extracts, with and without TGFβ stimulation. L) Luciferase TGFβ
transcriptional based assay showing increased pathway activation after TGFβ stimulation in Fibulin-4f/− VSMCs. Data is shown for 3 independent experiments with
n= 4–5 samples. Western blots for pSMAD2, SMAD2, SMA, SM22 and loading control β-catenin for Fibulin-4f/− VSMC protein extracts, with and without TGFβ
stimulation. Bars represent mean ± SD. Mann-Whitney test. * p < .05, $ p < .01 ‡ p < .001, # p < .0001.
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formation in aneurysmal disease. In contrast to Fibulin-4f/−/SM22Cre+
VSMCs, Fibulin-4R/R VSMCs show increased SMA protein levels. Re-
search by Ramnath et al. has shown increased SMA mRNA in Fibulin-
4R/R VSMCs [23]. Our current data now indicate that this increased
SMA expression is also translated into increased protein levels. From
literature it is known that TGFβ signaling is involved in VSMC differ-
entiation and induces expression of SMA and SM22 [35,36]. The in-
creased TGFβ signaling in Fibulin-4R/R VSMCs and aortas could
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therefore be responsible for the increased expression of SMA and SM22.
As previously mentioned, less distinct actin fibers have been found
in Fibulin-4GKO VSMCs by Huang et al. [24]. Yamashiro et al. in-
vestigated the actin fibers further in Fibulin-4f/−/SM22Cre+ aortas and
have shown that the ratio of F-actin to G-actin is significantly decreased
in the ascending aorta of Fibulin-4f/−/SM22Cre+ mice compared to
their controls [31]. This decrease in F-actin to G-actin is in line with our
results in VSMCs derived from Fibulin-4f/−/SM22Cre+ aortas, how-
ever, there is no significant decrease detected in Fibulin-4R/R VSMCs.
The decreased phosphorylated cofilin to cofilin ratio we observe in the
Fibulin-4f/−/SM22Cre+ VSMCs, which could result in increased de-
polymerization of actin, can explain the decrease in F-actin. The in-
teraction between actin dynamics and ECM composition, as we find for
Fibulin-4f/−/SM22Cre+ and Fibulin-4R/R VSMCs, has also been ob-
served for different biological systems and in different experimental set-
ups [37–39].
Increased activation of the TGFβ signaling pathway is often thought
to be causative in aneurysm formation. Yet, our results do not show
increased activation of the TGFβ pathway in Fibulin-4f/−/SM22Cre+
VSMCs. Recent data suggests a dual role for TGFβ signaling in an-
eurysm formation; while increased signaling can be protective in early
stages of the disease, it can be detrimental in later disease stages
[40,41]. This implies that disturbed TGFβ signaling is not the single
culprit in aneurysm formation. Our data also underlines the importance
of the cytoskeleton in aneurysm formation, since we show that Fibulin-
4 defects lead to cytoskeleton alterations. While Fibulin-4R/R VSMCs
show overproduction of the ECM, increased TGFβ signaling and in-
creased production of SMA, Fibulin-4f/−/SM22Cre+ VSMCs show less
ECM production, no increased TGFβ signaling and a lack of SMA pro-
duction and SMA fiber formation. This suggests that a defect in the ECM
protein fibulin-4 can lead to alterations of the cytoskeleton. Recent
research has shown the importance of the VSMC cytoskeleton in com-
bination with the ECM to contractility of the VSMCs and aneurysm
formation. Without proper connections of the cytoskeleton to the ECM,
a VSMC cannot generate force for its contractions. This shows that the
ECM and the cytoskeleton are of great importance for the contractility
of the aorta and may be primary drivers of thoracic aortic aneurysms
when these are defective [42].
Our data show that activation of the TGFβ pathway by TGFβ sti-
mulation is possible in Fibulin-4f/−/SM22Cre+ VSMCs and thus re-
ceptor expression and signal transduction is still intact. We show that
addition of exogenous TGFβ to Fibulin-4f/−/SM22Cre+ VSMCs results
in increased SMA protein levels. This result shows the direct inter-
connection between TGFβ pathway signaling and SMA protein levels.
From literature it is known that TGFβ is involved in VSMC differ-
entiation [43–45]. This differentiation is directly induced by TGFβ via
binding of SMAD3 to the SM22 promoter and induction of SMA pro-
duction via RhoA [46,47].
The difference in TGFβ pathway activation between the Fibulin-4f/
−/SM22Cre+ and Fibulin-4R/R mouse model could be the result of the
difference in ECM composition. The increased TGFβ levels in the
Fibulin-4R/R models is thought to be due to less stable binding of the
large latent complex (LLC) to fibrillin-1 [23]. Our data show increased
ECM deposition by Fibulin-4R/R VSMCs and increased amounts of
LTBP4, implicating higher bioavailability of TGFβ, together explaining
the augmented TGFβ activation. Furthermore, Bultmann-Mellin et al.
showed that LTBP4-L is needed for the deposition of fibulin-4 in the
ECM and thereby proper elastogenesis, and they showed a physical
interaction between LTBP4 and Fibulin-4 [48,49]. Increased TGFβ ac-
tivation in the Fibulin-4R/R model has previously been discovered by
RNA expression analysis of Fibulin-4R/R aortas and TGFβ cytokine
analysis in aortic extracts and blood of Fibulin-4R/R mice [23,50]. In
contrast, the less extensive ECM deposition we find in Fibulin-4f/
−/SM22Cre+ VSMCs could lead to decreased TGFβ signaling activity
since there is no properly formed ECM to bind the latent TGFβ.
Massam-Wu et al. have shown that fibulin-4 binds with high affinity to
LTBP1, a key mediator in binding of latent TGFβ in the ECM by binding
to LTBP4 as well as fibrillin-1 [51]. This suggests that Fibulin-4f/
−/SM22Cre+ VSMCs are unable to confine latent TGFβ in their matrix
due to the absence of Fibulin-4. Reduced storage of TGFβ could, in part,
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explain the decreased TGFβ signaling seen in Fibulin-4f/−/SM22Cre+
VSMCs. Especially since we show that exogenous addition of TGFβ is
able to activate the TGFβ pathway. Further research would be needed
to determine if the decrease in TGFβ signaling in Fibulin-4f/
−/SM22Cre+ VSMCs is caused by reduced production or secretion of
TGFβ.
Since depolymerization of actin fibers is needed for retraction of the
cells during migration [52,53], increased deposition of ECM proteins by
Fibulin-4R/R VSMCs in combination with increased production of SMA
and decreased depolymerization of the cytoskeleton could explain why
Fibulin-4R/R VSMCs show less migration compared to control VSMCs.
Furthermore, the more elaborate ECM of Fibulin-4R/R VSMCs could lead
to a stronger attachment to the culture plate, leading to less effective
migration. The increased SMA protein levels also implicates a more
contractile phenotype in Fibulin-4R/R VSMCs, as literature suggests less
migration for this contractile VSMC phenotype compared to the syn-
thetic VSMC phenotype [54]. Although Fibulin-4f/−/SM22Cre+ VSMCs
show less deposition of ECM proteins, their migration is still less ef-
fective compared to Fibulin-4f/+/SM22Cre+ VSMCs. In this case, the
reduced effective movement could be caused by the absence of SMA
fibers, less differentiation of the VSMCs and decreased attachment due
to the low ECM content. However, it remains to be determined if the
absence of Fibulin-4 and lack of ECM production by Fibulin-4f/
−/SM22Cre+ VSMCs is causative for the cytoskeleton alterations.
Our results show that while these reduction or absence of Fibulin-4
show opposite effects in cytoskeleton dynamics and TGFβ signaling,
both result in aneurysm formation in the mouse. Our data underlines
the need for new possible treatments of aneurysmal disease. Currently
most therapies are based on increased TGFβ signaling, while we show
that the Fibulin-4f/−/SM22Cre+ lack increased TGFβ signaling. Yet,
Fibulin-4f/−/SM22Cre+ mice do show aneurysm formation. Since both
Fibulin-4R/R and Fibulin-4f/−/SM22Cre+ mouse models show altera-
tions in the cytoskeleton, we propose that this is an additional under-
lying cause of aneurysm formation, which would be a potential target
for the development of novel therapies.
5. Conclusion
From these results we conclude that Fibulin-4 mutations lead to
SMA cytoskeleton instabilities as well as dysregulation of the TGFβ
pathway. However, reduced levels of Fibulin-4 have a strikingly dif-
ferent effect compared to the complete absence of Fibulin-4. When
Fibulin-4 is absent the production of ECM is reduced, the TGFβ pathway
is not activated and SMA is not produced. In contrast, reduced levels of
Fibulin-4 lead to excessive ECM deposition, over-activation of the TGFβ
pathway and cytoskeleton fibers aberrations. Although these models
show opposite effects, both mutations lead to aneurysm formation.
Moreover, we conclude that not only TGFβ signaling, but also cytos-
keleton dynamics could be causative for aortic aneurysmal disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.cellsig.2019.02.008.
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